Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market
LOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that…
